Lifevantage Corp
Business
LifeVantage Corp focuses on nutrigenomics, researching how nutrition and natural compounds affect gene expression to support health and wellness. It develops, formulates and sells dietary supplements, weight management products, pre- and pro-biotics, skin and hair care, pet supplements, and nootropic energy drink mixes under brands such as Protandim®, LifeVantage®, TrueScience®, PhysIQ™, Petandim®, and AXIO®. The company operates a direct selling business model built around independent consultants, supported by research and technology-enabled consultant training and loyalty programs. It distributes products primarily via independent consultants, company websites, subscription services and select international customer-only channels across the Americas, Asia/Pacific and Europe.
Summary from filing dated 2025-09-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue, net | 229 | 200 | 213 | 206 | 220 | |
| Cost of sales | 45 | 41 | 43 | 38 | 38 | |
| Gross profit | 184 | 159 | 170 | 168 | 182 | |
| Commissions and incentives | 102 | 86 | 95 | 97 | 104 | |
| Selling, general and administrative | 69 | 68 | 71 | 63 | 61 | |
| Total operating expenses | 171 | 154 | 166 | 161 | 164 | |
| Operating income | 12 | 4 | 4 | 8 | 18 | |
| Interest income, net | 431,000 | 430,000 | — | — | — | |
| Other expense, net | −387,000 | −412,000 | −458,000 | −669,000 | −366,000 | |
| Total other income, net | 44,000 | 18,000 | −260,000 | −3 | −383,000 | |
| Income before income taxes | 12 | 4 | 4 | 5 | 17 | |
| Income tax expense | −2 | −1 | −1 | −2 | −4 | |
| Net income | 10 | 3 | 3 | 3 | 13 | |
| Basic (dollars per share) | 0.8 | 0.24 | 0.2 | 0.24 | 0.92 | |
| Diluted (dollars per share) | 0.75 | 0.23 | 0.2 | 0.24 | 0.9 | |
| Basic (in shares) | 12 | 12 | 13 | 13 | 14 | |
| Diluted (in shares) | 13 | 13 | 13 | 13 | 14 | |
| Foreign currency translation adjustment | 741,000 | −555,000 | −238,000 | −1 | −40,000 | |
| Other comprehensive income (loss), net of tax: | 741,000 | −555,000 | −238,000 | −1 | −40,000 | |
| Comprehensive income | 11 | 2 | 2 | 2 | 13 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 20 | 17 | 22 | 20 | 23 | |
| Accounts receivable | 3 | 3 | 2 | 3 | 3 | |
| Income tax receivable | 635,000 | 313,000 | 241,000 | 2 | 1 | |
| Inventory | 21 | 15 | 16 | 16 | 16 | |
| Prepaid expenses and other | 6 | 2 | 5 | 5 | 5 | |
| Total current assets | 51 | 38 | 44 | 47 | 48 | |
| Property and equipment, net | 6 | 8 | 9 | 10 | 11 | |
| Right-of-use assets | 8 | 10 | 9 | 11 | 14 | |
| Intangible assets, net | 245,000 | 323,000 | 455,000 | 587,000 | 719,000 | |
| Deferred income tax asset | 6 | 4 | 3 | 1 | 1 | |
| Other long-term assets | 601,000 | 680,000 | 569,000 | 1 | 2 | |
| TOTAL ASSETS | 72 | 60 | 66 | 71 | 79 | |
| Accounts payable | 5 | 6 | 4 | 7 | 7 | |
| Commissions payable | 7 | 7 | 7 | 7 | 8 | |
| Income tax payable | 0 | 202,000 | 0 | 453,000 | 830,000 | |
| Lease liabilities | 2 | 2 | 2 | 3 | 2 | |
| Other accrued expenses | 14 | 8 | 8 | 8 | 7 | |
| Total current liabilities | 27 | 22 | 20 | 26 | 25 | |
| Long-term lease liabilities | 10 | 12 | 12 | 13 | 16 | |
| Other long-term liabilities | 289,000 | 198,000 | 299,000 | 308,000 | 694,000 | |
| Total liabilities | 37 | 34 | 31 | 39 | 42 | |
| Commitments and contingencies Note 14 | — | — | — | — | — | |
| Preferred stock par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding | 0 | 0 | 0 | 0 | 0 | |
| Common stock par value $0.0001 per share, 40,000 shares authorized and 12,429 and 12,510 issued and outstanding as of June 30, 2025 and 2024, respectively | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |
| Additional paid-in capital | 140 | 137 | 134 | 131 | 129 | |
| Accumulated deficit | −104 | −109 | −98 | −98 | −92 | |
| Accumulated other comprehensive loss | −1 | −2 | −1 | −1 | 104,000 | |
| Total stockholders equity | 35 | 26 | 35 | 32 | 37 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 72 | 60 | 66 | 71 | 79 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 3 | 4 | 4 | 3 | 3 | |
| Stock-based compensation | 6 | 3 | 3 | 2 | 2 | |
| Non-cash operating lease expense | 1 | 1 | 2 | 2 | 2 | |
| (Gain) loss on disposal of fixed assets | −4,000 | 2,000 | 33,000 | 0 | −7,000 | |
| Amortization of deferred financing fees | 32,000 | 7,000 | 0 | 0 | 0 | |
| Deferred income tax | −2 | −1 | −2 | −81,000 | 955,000 | |
| Accounts receivable | −242,000 | −1 | 2 | −614,000 | −265,000 | |
| Income tax receivable | −322,000 | −71,000 | 2 | −713,000 | −1 | |
| Inventory | −5 | 662,000 | 61,000 | −1 | −2 | |
| Prepaid expenses and other | −4 | 2 | 1 | −551,000 | 486,000 | |
| Other long-term assets | 72,000 | −55,000 | −157,000 | 139,000 | 59,000 | |
| Accounts payable | −1 | 2 | −4 | 824,000 | 3 | |
| Income tax payable | −201,000 | 202,000 | −453,000 | −377,000 | 46,000 | |
| Other accrued expenses | 6 | −176,000 | −770,000 | 357,000 | −4 | |
| Lease liabilities | −2 | −2 | −2 | −2 | −2 | |
| Other liabilities | 63,000 | 247,000 | 257,000 | −335,000 | −293,000 | |
| Net Cash Provided by Operating Activities | 12 | 12 | 7 | 8 | 16 | |
| Purchase of equipment | −1 | −2 | −3 | −2 | −4 | |
| Proceeds from sale of fixed assets | 4,000 | 0 | 8,000 | 0 | 7,000 | |
| Net Cash Used in Investing Activities | −1 | −2 | −3 | −2 | −4 | |
| Payment of deferred financing fees | 0 | −97,000 | 0 | — | — | |
| Repurchase of company stock | −3 | −6 | −800,000 | −9 | −12 | |
| Payment of cash dividends | −2 | −7 | −2 | −378,000 | 0 | |
| Shares purchased as payment of tax withholding and other | −3 | −1 | −201,000 | −246,000 | −1 | |
| Proceeds from common stock issued under employee stock purchase plan | 280,000 | 271,000 | 252,000 | 372,000 | 517,000 | |
| Net Cash Used in Financing Activities | −8 | −14 | −2 | −9 | −11 | |
| Foreign Currency Effect on Cash | 402,000 | −254,000 | 3,000 | −461,000 | −50,000 | |
| Increase (Decrease) in Cash and Cash Equivalents | 3 | −5 | 1 | −3 | 1 | |
| Cash paid for interest | 2,000 | 21,000 | 5,000 | 10,000 | 17,000 | |
| Cash paid for income taxes | 5 | 2 | 2 | 3 | 4 |